Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13239699 | 0.90 | KDM4E (0.49) | SMN1; SMN2ALDH1A1LMNATDP1GAA | |
| SCHEMBL12422454 | 0.89 | KDM4E (0.46) | SMN1; SMN2ALDH1A1LMNAKMT2ATDP1 | |
| SCHEMBL1529096 | 0.88 | ATM (0.52) | ATMSMN1; SMN2ALDH1A1L3MBTL1LMNA | |
| SCHEMBL12422449 | 0.87 | KDM4E (0.48) | SMN1; SMN2ALDH1A1LMNAKMT2ATDP1 | |
| SCHEMBL12422456 | 0.87 | KDM4E (0.48) | SMN1; SMN2ALDH1A1LMNAKMT2ATDP1 | |
| SCHEMBL12422450 | 0.87 | KDM4E (0.48) | SMN1; SMN2ALDH1A1LMNAKMT2ATDP1 | |
| SCHEMBL23871040 | 0.87 | ATM (0.48) | ATMSMN1; SMN2ALDH1A1L3MBTL1LMNA | |
| SCHEMBL12422483 | 0.87 | ATM (0.48) | ATMSMN1; SMN2ALDH1A1L3MBTL1LMNA | |
| SCHEMBL19718348 | 0.85 | LMNA (0.47) | ATMSMN1; SMN2ALDH1A1L3MBTL1LMNA | |
| SCHEMBL2682453 | 0.85 | KMT2A (0.47) | ATMSMN1; SMN2ALDH1A1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11822245-B2 | Resist composition and pattern forming process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-21 | — | — | US | disclosed |
| US-11822245-B2 | Resist composition and pattern forming process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-21 | — | — | US | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20220402940-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220119407-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-04-21 | — | — | US | disclosed |
| US-11236109-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210302837-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-09-30 | — | — | US | disclosed |
| US-20210302838-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-09-30 | — | — | US | disclosed |
| US-11053195-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-7468373-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080233518-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND MANUFACTURING METHOD OF SEMICONDUCTOR INTEGRATED CIRCUIT DEVICE WITH SUCH CHEMICALLY AMPLIFIED RESIST COMPOSITION | NEC ELECTRONICS CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| US-7396633-B2 | Damascene process; forming connectors; exposure; development; using acid generator, quencher and buffer | NEC ELECTRONICS CORPORATION (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7345052-B2 | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-20070155760-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-05 | — | — | US | disclosed |
| US-20040259029-A1 | Chemically amplified resist composition and manufacturing method of semiconductor integrated circuit device with such chemically amplified resist composition | NEC ELECTRONICS CORPORATION (JP) | 2004-12-23 | — | — | US | disclosed |
| US-6749988-B2 | PREVENTING A RESIST FILM FROM THINNING AND ALSO FOR ENHANCING THE RESOLUTION AND FOCUS MARGIN OF RESIST; HETEROCYCLIC AMINE COMPOUNDS HAVING A HYDRATING GROUP SUCH AS A HYDROXY, ETHER, ESTER, CARBONYL, CARBONATE GROUP OR LACTONE RING | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2004-06-15 | — | — | US | disclosed |
| US-20020098443-A1 | Amine compounds, resist compositions and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119407-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ATM 3017/4885SMN1; SMN2 1176/4885ALDH1A1 1089/4885 |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ATM 3017/4885SMN1; SMN2 1176/4885ALDH1A1 1089/4885 |
| US-20020098443-A1 | Amine compounds, resist compositions and patterning process | PARG, EHMT1, EHMT2 | ATM 2140/4885SMN1; SMN2 2840/4885ALDH1A1 4186/4885 |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | ATM 2210/4885SMN1; SMN2 3557/4885ALDH1A1 680/4885 |
| US-20220402940-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ATM 3017/4885SMN1; SMN2 1176/4885ALDH1A1 1089/4885 |
| US-11236109-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | ATM 3017/4885SMN1; SMN2 1176/4885ALDH1A1 1089/4885 |
| US-20070155760-A1 | ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND RELATED THERAPEUTIC AND PROPHYLACTIC METHODS | ADORA2A, ADORA1, ADORA3 | ATM 1582/4885SMN1; SMN2 3498/4885ALDH1A1 192/4885 |
| US-11053195-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | ATM 3017/4885SMN1; SMN2 1176/4885ALDH1A1 1089/4885 |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | ATM 3017/4885SMN1; SMN2 1176/4885ALDH1A1 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.